Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

This study has been withdrawn prior to enrollment.
(Trial terminated - Nanoscale Company out of business)
Sponsor:
Information provided by (Responsible Party):
University of Kansas
ClinicalTrials.gov Identifier:
NCT01707758
First received: October 12, 2012
Last updated: May 15, 2013
Last verified: May 2013

October 12, 2012
May 15, 2013
October 2012
February 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01707758 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence
Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence

The primary objective is to develop a rapid in vitro screening assay for detection of pancreatic cancer biomarkers in blood of patients with pancreatic cancer.

The goal of the project is to develop a rapid in vitro screening assay for detection of cancer biomarkers in blood. The aim is testing and optimization of nanoparticle sensors, based on cyanine dyes that are chemically linked to Fe/Fe3O4 nanoparticles via protease-selective consensus (cleavage) sequences. The focus is on the quantitative determination of active cancer-specific proteases in blood via simple fluorescence measurements. The matrix metalloproteinases, urokinase-type plasminogen activator, and cathepsins, are up-regulated in the vast majority of progressing cancers and can, therefore, serve as markers for cell survival/tumor progression, angiogenesis, and tissue remodeling/invasion

Observational
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:

Approximately 1 tablespoon of blood will be collected from each subject.

Probability Sample

Patients will be recruited from the University of Kansas Cancer Center prior to any treatment for their pancreatic cancer. Final histology and staging will be recorded and correlated with protease concnentration. Healthy subjects will be recruited from the University of Kansas and Kansas State community.

Pancreatic Cancer
Not Provided
pancreatic cancer
This study will collect blood from 36 patients with known or suspected pancreatic cancer and from 12 healthy cancer-free subjects.
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
February 2013
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Inclusion Criteria for Pancreatic Cancer Patients:

  • Patients will either have a histologic diagnosis of pancreatic carcinoma or a clinical picture consistent with pancreatic cancer and will be undergoing surgery or a diagnostic procedure to confirm the diagnosis.
  • Patients will have had no prior treatment or surgery

Inclusion Criteria for Healthy Subjects:

  • Subjects will have no prior history of any cancer

Exclusion Criteria:

Exclusion Criteria for Pancreatic Cancer Patients

  • Any prior treatment for pancreatic cancer
  • Poorly controlled diabetes

Exclusion Criteria for Healthy Subjects

  • Poorly controlled diabetes
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01707758
13421
Yes
University of Kansas
University of Kansas
Not Provided
Principal Investigator: Stephen Williamson, MD University of Kansas Medical Center Cancer Center
University of Kansas
May 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP